Keros Therapeutics(US:KROS)2026-03-04 21:02Financial Performance - Keros reported a net loss of $23.5 million for Q4 2025, a significant improvement from a net loss of $46.0 million in Q4 2024, and achieved a net income of $87.0 million for the full year 2025 compared to a net loss of $187.4 million in 2024[3] - Total revenue for 2025 was $244.1 million, with license revenue contributing $205.4 million, compared to $3.0 million in 2024[14] - Keros' accumulated deficit improved to $481.8 million as of December 31, 2025, from $568.8 million in 2024[16] Expenses - Research and development expenses decreased to $17.9 million in Q4 2025 from $45.6 million in Q4 2024, and for the full year, expenses were $129.6 million compared to $173.6 million in 2024[4] - General and administrative expenses increased to $11.7 million in Q4 2025 from $10.7 million in Q4 2024, and for the full year, they rose to $46.8 million from $40.8 million in 2024[5] Cash and Assets - Keros' cash and cash equivalents as of December 31, 2025, were $287.4 million, down from $559.9 million at the end of 2024, primarily due to share repurchases and cash tender offers[7] - Keros' total assets decreased to $338.0 million as of December 31, 2025, from $615.9 million in 2024, reflecting a reduction in cash and cash equivalents[16] - The company expects its cash reserves will fund operations into the first half of 2028 based on current operating assumptions[7] Future Plans - The company plans to initiate a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy (DMD) in Q2 2026 and engage regulators for a Phase 2 trial in amyotrophic lateral sclerosis (ALS) in H2 2026[5] Stock Information - The weighted-average common stock outstanding was 27,198,653 for Q4 2025, compared to 40,337,720 for Q4 2024[14]